Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
71,366,920
-
Number of holders
-
120
-
Total 13F shares, excl. options
-
37,306,180
-
Shares change
-
+1,395,546
-
Total reported value, excl. options
-
$904,604,832
-
Value change
-
+$6,530,479
-
Put/Call ratio
-
75%
-
Number of buys
-
71
-
Number of sells
-
51
-
Price
-
$24.26
Institutional Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) as of Q1 2022
As of 31 Mar 2022 C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) had 120 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 37,306,180 shares of stock of the company.
Largest 10 holders included RTW INVESTMENTS, LP, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., STATE STREET CORP, PERCEPTIVE ADVISORS LLC, VANGUARD GROUP INC, ArrowMark Colorado Holdings LLC, Bain Capital Life Sciences Investors, LLC, WASATCH ADVISORS INC, and PICTET ASSET MANAGEMENT SA.
This table shows 120 institutional shareholders of the security as of 31 Mar 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.